Trial Profile
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics; ZIOPHARM Oncology
- 21 Sep 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results (n=38) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 29 May 2020 According to an ZIOPHARM Oncology media release, data from this study was presented at the 2020 American Society of Clinical Oncology (ASCO) Annual (Virtual) Meeting.